Topical and Conventional Systemic Treatments in Atopic Dermatitis: Have They Gone Out of Fashion?
Giulia Calabrese, Gaetano Licata, Alessio Gambardella, Alina De Rosa, Roberto Alfano, Giuseppe Argenziano
Abstract
Atopic dermatitis is a Th2 disease, due to relapse of IL-4 and IL-13 by Th2 cells. Despite the approval by FDA of dupilumab, the first monoclonal antibody for the severe forms, traditional drugs remain a milestone for the treatment of this dermatosis. Dermatologists need a good knowledge of all therapies for an integrated and personalized management of patients.
Topics & Concepts
DupilumabMedicineAtopic dermatitisMilestoneDermatologyBiologic AgentsMonoclonal antibodyDiseaseImmunologyAntibodyPathologyArchaeologyHistoryDermatology and Skin DiseasesAllergic Rhinitis and SensitizationContact Dermatitis and Allergies